The Official MicroCap News Source
Watchlist News
Please Login or Register to view News Stories

Healthcare & Insurance

U. S. FDA Grants Clearance for Ion by Intuitive

Flexible robotic catheter helps physicians reach nodules in the peripheral lungSUNNYVALE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the

Tuesday, February 19, 2019

BioCorRx Announces Formation of Scientific Advisory Board

ANAHEIM, CA, Feb. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today the formation of its Scientific Advisory Board (SAB) with three key

Tuesday, February 19, 2019

Diamond CBD Books Over $200,000 in Orders in 3 Days at Tobacco Plus Expo in Las Vegas

Company describes show as extremely successful with many new wholesale customers added to its already extensive client rosterFT LAUDERDALE, Fla., Feb. 19, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Diamond CBD Inc., a wholly-owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN) and a

Tuesday, February 19, 2019

TOMI Environmental Solutions, Inc. Announces Relocation of Its U.S. Corporate Headquarters

BEVERLY HILLS, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (OTCQX:TOMZ), a global company that specializes in disinfection and decontamination essentials using its premier Binary Ionization Technology® (BIT™) platform through the manufacturing,

Tuesday, February 19, 2019

Pernix Therapeutics Holdings, Inc. Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management

Transaction that includes the sale of substantially all of Pernix’s assets to be valued at $75.6 million             Pernix voluntarily files for Chapter 11 protection Pernix intends to continue to operate with no disruption to the availability of Pernix products and patient

Tuesday, February 19, 2019

MediPharm Labs Announces Listing on Frankfurt Stock Exchange

TORONTO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MLCPF) (FSE:MLZ) (“MediPharm”) a leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that its common shares are now listed

Tuesday, February 19, 2019

Beazley healthcare premium return facility hits $10m milestone in the United States

London, Feb. 19, 2019 (GLOBE NEWSWIRE) -- A Beazley facility to support improvements to patient quality and safety standards by offering hospitals and health systems a discount on their insurance premium has resulted in savings for clients of more than $10 million.Beazley’s Quality Indicator

Tuesday, February 19, 2019

Generex Biotechnology Subsidiary Regentys Corporation Receives Approval of Japanese Patent for Extracellular Matrix Hydrogel (Regentys ECMH™)

MIRAMAR, FL, Feb. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company’s subsidiary Regentys Corporation, a clinical stage regenerative medicine

Tuesday, February 19, 2019

Radius Health to Present at Leerink Partners 8th Annual Global Healthcare Conference

WALTHAM, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at the Leerink Partners 8th Annual Global Healthcare Conference on Friday, March 1, 2019. Information on

Tuesday, February 19, 2019

Innovation Pharmaceuticals Receives New Patent for Compounds for Use in Treatment of Oral Mucositis

BEVERLY, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the U.S. Patent & Trademark Office issued today a new patent to the Company for the treatment of oral

Tuesday, February 19, 2019

RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of

Glen Rock, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the treatment of sleep-related breathing disorders, is pleased to announce that it has entered into

Tuesday, February 19, 2019

Precision Therapeutics Inc. is Excited to Announce a Special Meeting of Stockholders and Commencement of Registered Exchange Offer

MINNEAPOLIS, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision”) today announced the effectiveness of its Form S-4 registration statement, the establishment of the date of its special meeting of stockholders in connection with the proposed business

Tuesday, February 19, 2019

Canada House Wellness Group Announces Unit Financing for $2 to $3 Million

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc. (CSE: CHV) (“Canada House” or the “Company”) announces that it intends to proceed with a financing of units (“Units”) for

Tuesday, February 19, 2019

Letter to Shareholders from Curt Fairbrother, CEO The Medtainer™

CORONA, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dear Shareholders- I know that you haven’t heard from us in a while, and I apologize for that. I assure you that it was not by omission but by design. The end of 2018 and the beginning of 2019 have been tremendous for our company from several

Tuesday, February 19, 2019

VistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced

Tuesday, February 19, 2019

Assertio Therapeutics Announces FDA Notification of Acceptance for Filing of 505(b)(2) NDA for Long-acting Cosyntropin

Company Anticipates Potential Market Launch by Early 2020LAKE FOREST, Ill., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that it has received notification of acceptance for filing from the U.S. Food and Drug Administration (FDA) for its 505(b)(2)

Tuesday, February 19, 2019

Nuvectra to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019

PLANO, Texas, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter and full year ended December 31, 2018 on Thursday, February 28, 2019 after market

Tuesday, February 19, 2019

Cerecor Receives Fast Track Designation from FDA for CERC-801 for the Treatment of PGM1 Deficiency

ROCKVILLE, Md., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug

Tuesday, February 19, 2019

MediPharm Labs Announces Listing on Frankfurt Stock Exchange

TORONTO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MLCPF) (FSE:MLZ) (“MediPharm”) a leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that its common shares are now listed

Tuesday, February 19, 2019

BrainStorm Issues a Statement to Patients and Shareholders

NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, in response to numerous requests, issues today the following statement: We will

Tuesday, February 19, 2019

loading

© 2019 Stock News Now